Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lifestyle modification

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    46 result(s) found for: Lifestyle modification. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2021-006069-39 Sponsor Protocol Number: LPS16141 Start Date*: 2022-06-26
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A Randomized, Double-Blind, Parallel-Group Clinical Trial to Assess the Efficacy of Essentiale on Hepatic Steatosis Added to Standard of Care Versus Placebo Added to Standard of Care, in Non-Alcoho...
    Medical condition: Non-alcoholic fatty liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesity
    Disease: Version SOC Term Classification Code Term Level
    25.0 100000004871 10082249 Nonalcoholic fatty liver disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-012011-17 Sponsor Protocol Number: H8O-MC-GWDE Start Date*: 2009-11-19
    Sponsor Name:Eli Lilly and Company
    Full Title: Safety and Efficacy of Exenatide Once Weekly versus Liraglutide in subjects with type 2 diabetes and inadequate glycemic control treated with lifestyle modification and oral antidiabetic medications
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) FR (Completed) ES (Completed) BE (Completed) SK (Completed) IT (Completed) AT (Completed) GR (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-001356-36 Sponsor Protocol Number: 20131 Start Date*: 2013-10-10
    Sponsor Name:"G. d'Annunzio" University
    Full Title: Effects of liraglutide or lifestyle counselling on subcutaneous adipose tissue and visceral adipose tissue distribution, circulating adipokine concentration, insulin sensitivity and beta-cell perfo...
    Medical condition: Obesity with a diagnosis of impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) or type 2 Diabetes Mellitus (T2DM) for less than 12 months, according to the American Diabetes Associa...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2024-000081-22 Sponsor Protocol Number: I8F-MC-GPHV Start Date*: 2024-03-07
    Sponsor Name:Eli Lilly and Company
    Full Title: A Safety, Tolerability and Pharmacokinetic Study of Tirzepatide for the Treatment of Pediatric Participants (6 years to 11 years) with Obesity.
    Medical condition: Weight management
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10027428 Metabolic disorders NEC HLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2020-003742-36 Sponsor Protocol Number: MK-3475-02D Start Date*: 2021-02-16
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc
    Full Title: A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D
    Medical condition: Melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) GR (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-004492-38 Sponsor Protocol Number: PUMA-NER-1301 Start Date*: 2013-07-30
    Sponsor Name:Puma Biotechnology, Inc.
    Full Title: A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2-Directed Regimens in the Metastati...
    Medical condition: HER2+ Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FI (Completed) IT (Completed) BE (Completed) CZ (Completed) ES (Completed) AT (Completed) SE (Completed) IE (Completed) DK (Prematurely Ended) PT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002571-24 Sponsor Protocol Number: 15/0118 Start Date*: 2016-10-14
    Sponsor Name:Joint Research Office
    Full Title: A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients with Parkinson Disease: Ambroxol in Diseas...
    Medical condition: Parkinson disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-007026-22 Sponsor Protocol Number: CL2-09490-157 Start Date*: 2008-03-28
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Assessment of the effects on 24-hour ambulatory blood pressure and the safety of a once-a-day oral 8 mg perindopril morning administration versus evening administration in hypertensive patients. An...
    Medical condition: Essential arterial hyperpertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005196-16 Sponsor Protocol Number: H8O-MC-GWBQ Start Date*: 2012-07-24
    Sponsor Name:Amylin Pharmaceuticals, Inc.
    Full Title: Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents with Type 2 Diabetes
    Medical condition: Treatment of Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10012594 Diabetes LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-001731-28 Sponsor Protocol Number: C LF 23-0121 0401 Start Date*: 2004-09-24
    Sponsor Name:FOURNIER Laboratories Ireland
    Full Title: A double-blind, 3-arm study on weight loss with combination of micronised fenofibrate 267 mg and metformin 1700 mg per day compared to metformin 1700 mg and placebo, at 6 months, in obese patients,...
    Medical condition: Obesity
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2014-004353-14 Sponsor Protocol Number: NN8022-4180 Start Date*: 2016-08-15
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of liraglutide for weight management in pubertal adolescent subjects with obesity. 56-week, double-blind, randomised, parallel-group, placebo-controlled multi-national trial followed by a 26...
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    19.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000240-27 Sponsor Protocol Number: 01-06-TL-SYR472-007 Start Date*: 2007-05-25
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd
    Full Title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate Weekly Treatment with SYR-472 in Subjects with Type 2 Diabetes.
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) LT (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2021-006038-37 Sponsor Protocol Number: TAK-573-1501 Start Date*: 2022-10-11
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refr...
    Medical condition: Relapsed/Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed) DE (Prematurely Ended) FR (Completed) IE (Completed) ES (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001824-32 Sponsor Protocol Number: 116174 Start Date*: 2015-03-05
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in pa...
    Medical condition: Diabetes mellitus type 2
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) CZ (Completed) GB (Completed) SE (Completed) NL (Completed) HU (Completed) BE (Completed) DK (Completed) ES (Completed) BG (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-000546-34 Sponsor Protocol Number: NN8022-4392 Start Date*: 2021-02-10
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of liraglutide 3.0 mg on weight management in children with obesity aged 6 to <12 years: 56-week, double-blind, randomised, placebo-controlled trial
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) PT (Trial now transitioned) NO (Not Authorised)
    Trial results: (No results available)
    EudraCT Number: 2012-002866-11 Sponsor Protocol Number: TRx-237-015 Start Date*: 2013-01-23
    Sponsor Name:TauRx Therapeutics Ltd
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer's Disease
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-002847-28 Sponsor Protocol Number: TRx-237-005 Start Date*: 2013-04-11
    Sponsor Name:TauRx Therapeutics Ltd
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild Alzheimer’s Disease
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) NL (Completed) ES (Completed) FI (Completed) IT (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2006-003076-35 Sponsor Protocol Number: F3Z-VI-S019 Start Date*: 2006-09-26
    Sponsor Name:Eli Lilly and Company Ltd.
    Full Title: Treatment Strategies in Patients with Type 2 Diabetes Mellitus Not Achieving Glycemic Control while on Therapy with Premixed Insulin Analogues and Metformin: A Comparison of Insulin Lispro MM Inte...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    8.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006712-93 Sponsor Protocol Number: MK-1088-002 Start Date*: 2022-06-09
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
    Medical condition: Advanced/metastatic solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2022-003205-29 Sponsor Protocol Number: CAP2022-1 Start Date*: 2023-02-23
    Sponsor Name:Aphaia Pharma US LLC
    Full Title: A Phase II, randomized, placebo – controlled crossover proof-of-concept study to evaluate efficacy and safety of distal jejunal-release dextrose beads formulation (APHD-012) in subjects with a path...
    Medical condition: Subjects with a pathological Oral Glucose Tolerance Test (OGTT)
    Disease: Version SOC Term Classification Code Term Level
    24.0 100000004861 10065542 Prediabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 14:23:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA